نبذه عن الشركة
Gilead Sciences, Inc. discovers, develops and commercializes therapeutics to advance the care of patients with life-threatening diseases. For the 6 months ended 6/30/05, revenues rose 47% to $925.7M. Net income rose 56% to $353.1M. Revenues reflect increased sales volume within HIV product franchise. Higher income also reflects lower SG&A expenses as a percentage of sales and an increase in interest and other income
الاشارة شمعة الديلى غالبا مايصحبها ارتفاعات
تحديد نقطة الدخول على ضوء الافتتاح فى الغد باذن الله
|
 |
 |
|||
 |
 |
||||
رد مع اقتباس
المفضلات